BIIB

The controversy surrounding biotechnology firm Biogen’s (NASDAQ: BIIB) Alzheimer’s drug Aducanumab took a positive turn last week after the FDA…

Biogen Inc. (NASDAQ: BIIB) Q3 2020 earnings call dated Oct. 21, 2020 Corporate Participants: Joe Mara — Head of Investor Relations Michel Vounatsos — Chief…

Biogen Inc. (NASDAQ: BIIB) Q2 2020 earnings call dated July 22, 2020 Corporate Participants: Joe Mara — Vice President of Finance and…

Biogen (NASDAQ: BIIB) reported a 12% increase in adjusted EPS and 2% growth in revenue for the second quarter of…

Biogen Inc (BIIB) Q1 2020 earnings call dated Apr. 22, 2020 Corporate Participants: Joe Mara — Vice President, Investor Relations Michel Vounatsos — Chief…

Biogen Inc. (NASDAQ: BIIB) reported its financial results for the quarter ended March 31, 2020 today. Biogen posted a 1%…

Biogen Inc  (BIIB) Q4 2019 earnings call dated Jan. 30, 2020 Corporate Participants: Joe Mara — Vice President, Investor Relations Michel Vounatsos — Chief…

— Biogen Inc. (NASDAQ: BIIB) reported its fourth-quarter 2019 adjusted earnings of $8.34 per share versus $8.02 per share expected.…

Biogen Inc. (NASDAQ: BIIB) reported a 7% increase in earnings for the third quarter of 2019 as spinal muscular atrophy…

The market value of pharma giant Biogen, Inc. (NASDAQ: BIIB) declined by a third in March when the stock suffered…